New Zealand to outline pros and cons of prostate cancer testing in new guidelines:
This article was originally published in Clinica
Executive Summary
New Zealand is to outline the pros and cons of the prostate specific antigen (PSA) diagnostic blood test in a new guidance document to be developed early next year. Currently, New Zealand does not recommend routine screening without symptoms. Along with other countries such as the US it has found that the test is not 100% accurate. It may miss some cancers or detect some slow-growing prostate cancers, which may not prove life threatening, in which case detection results in unnecessary anxiety, further tests or treatment that may be harmful or uncomfortable. The advice, to be jointly developed by the Prostate Cancer Foundation and the ministry of health, will enable patients and doctors to make an informed decision on whether to undergo a test or not.
You may also be interested in...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.